SLXN fundamentals
An in-depth look to Silexion Therapeutics Corp operating, investing, and financing activities
SLXN free cash flow for Q2 24 is -103.34 k USD. For 2023, SLXN free cash flow was 306.38 k USD and operating cash flow was 306.38 k USD.
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM